Patents by Inventor Rachel Siegel

Rachel Siegel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Repressor on IFN-? promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-? gene activity
    Patent number: 8933049
    Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: January 13, 2015
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale, Adam Swider
  • Repressor on IFN-? promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-? gene activity
    Patent number: 8802648
    Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: August 12, 2014
    Inventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale
  • NOVEL REPRESSOR ON IFN-LAMBDA PROMOTER AND SIRNA AGAINST ZEB1 AND BLIMP-1 TO INCREASE IFN-LAMBDA GENE ACTIVITY
    Publication number: 20130338211
    Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases.
    Type: Application
    Filed: December 4, 2012
    Publication date: December 19, 2013
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Grant Gallagher, Rachel Siegel, Joyce Eskdale